Certain Class B Ordinary Shares of Biotech Acquisition Company are subject to a Lock-Up Agreement Ending on 25-JUL-2021. These Class B Ordinary Shares will be under lockup for 181 days starting from 25-JAN-2021 to 25-JUL-2021.

Details:
Sponsor and directors and officers have agreed that will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, without the prior written consent of Cantor Fitzgerald & Co., for a period of 180 days after the date of this prospectus, any units, warrants, ordinary shares or any other securities convertible into, or exercisable, or exchangeable for, ordinary shares; provided, however, that may (1) issue and sell the private placement warrants; (2) issue and sell the additional units to cover underwriters' over-allotment option (if any); (3) register with the SEC pursuant to an agreement to be entered into concurrently with the issuance and sale of the securities in this offering, the resale of the private placement warrants and the Class A ordinary shares issuable upon exercise of the warrants and the founder shares; and (4) issue securities in connection with initial business combination. However, the foregoing shall not apply to the forfeiture of any founder shares pursuant to their terms or any transfer of founder shares to any current or future independent director of the company (as long as such current or future independent director transferee is subject to the letter agreement, filed herewith, or executes an agreement substantially identical to the letter agreement, as applicable to directors and officers at the time of such transfer; and as long as, to the extent any Section 16 reporting obligation is triggered as a result of such transfer, any related Section 16 filing includes a practical explanation as to the nature of the transfer). Cantor Fitzgerald & Co., in its sole discretion may release any of the securities subject to these lock-up agreements at any time without notice.